aTyr Pharma ATYR 深 沪
已收盘 07-02 16:00:00 美东时间
0.5925
+0.003
+0.46%
华盛通- 最 高0.6062
- 今 开0.5898
- 成交量 147.65万股
- 最 低 0.5733
- 昨 收 0.5898
- 总市值 5809.53万
- 52周最高 7.2904
- 市盈率 静 --
- 换手率 1.51%
- 52周最低 0.395
- 委 比 78.60%
- 总股本 9805.12万
- 历史最高 396.06
- 量 比 0.41
- 振 幅 5.58%
- 历史最低 0.395
- 每 手 1
- 风险率 1.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多aTyr Pharma Granted Nasdaq Extension to Regain Compliance
aTyr Pharma ( ($ATYR) ) has provided an announcement. On December 4, 2025, aTyr...
06-09 05:12
aTyr Pharma Q1 EPS $(0.11) Beats $(0.14) Estimate
aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 35.29 percent increase over losses of $(0.17) per share from the
05-15 20:17
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock moved upwards by 79.4% to $12....
05-13 01:06
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
aTyr Pharma announced plans to advance efzofitimod for pulmonary sarcoidosis following FDA feedback. The company will initiate a new Phase 3 study targeting patients with chronic, symptomatic pulmonary sarcoidosis and restrictive lung disease, using forced vital capacity (FVC) as the primary endpoint and the King’s Sarcoidosis Questionnaire (KSQ)-Lung score as a key secondary endpoint. The IND submission for this trial is planned for June 2026. T...
05-11 20:01
aTyr Pharma GAAP EPS of -$0.14 beats by $0.02
aTyr Pharma press release (ATYR): Q4 GAAP EPS of -$0.14 beats by $0.02. Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments. More on aTyr Pharma aTyr Pharma to mee...
03-06 14:24
aTyr Pharma Q4 EPS $(0.14) Beats $(0.16) Estimate
aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 13.04 percent. This is a 22.22 percent increase over losses of $(0.18) per share from the
03-06 05:03
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
Company to meet with FDA in mid-April 2026 to review Phase 3 EFZO-FIT™ study results in pulmonary sarcoidosis. Phase 2 EFZO-CONNECT™ study enrollment on track for 2026. Ended 2025 with $80.9M in cash. R&D expenses were $60.2M, G&A expenses were $17.6M. Efzofitimod showed clinical benefits in multiple endpoints but did not meet primary endpoint. Promising interim data from Phase 2 EFZO-CONNECT™ study. ATYR0101 demonstrated favorable profile. Publi...
03-05 21:01
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
aTyr Pharma, a clinical stage biotechnology company, announced that its CEO, Sanjay S. Shukla, M.D., M.S., will present at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2026. The presentation will cover the company’s tRNA synthetase platform and its lead candidate, efzofitimod, for treating fibrosis and inflammation. The webcast and replay will be available on the company’s website. aTyr leverages evolutionary intelligen...
02-18 13:00
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
aTyr Pharma announced the FDA has accepted its request for a Type C meeting to discuss efzofitimod for pulmonary sarcoidosis, scheduled for mid-April 2026. The Phase 3 EFZO-FIT™ study of 268 patients showed clinical benefits across multiple endpoints despite not meeting the primary endpoint. Efzofitimod, a biologic immunomodulator, selectively modulates myeloid cells to resolve inflammation and prevent fibrosis, with a favorable safety profile. T...
02-03 13:00
aTyr Pharma Faces Investor Class Action After Drug Trial Failure
aTyr Pharma Inc. is facing a class action securities lawsuit filed on behalf of investors who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that aTyr Pharma mad...
2025-12-03 20:39
